661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype

• Vincent O’Neill,
• Veena Agarwal,
• Moses K Donkor,
• Sherry Kupchick,
• Rashmi Deshpande,
• Dawn Newmin

Affiliations

Vincent O’Neill

2Bioxcel Therapeutics, Madison, CT, USA

Veena Agarwal

Immune-oncology, BioXcel Therapeutics Inc, New Haven, Connecticut, USA

Moses K Donkor

Bioxcel Therapeutics, New Haven, CT, USA

Sherry Kupchick

Bioxcel Therapeutics, New Haven, CT, USA

Rashmi Deshpande

Bioxcel Therapeutics, New Haven, CT, USA

Dawn Newmin

Bioxcel Therapeutics, New Haven, CT, USA